WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19

WHO today accepted the recommendation from the Solidarity Trial’s International Steering Committee to discontinue the trial’s hydroxychloroquine and lopinavir/ritonavir arms. The Solidarity Trial was established by WHO to find an effective COVID-19 treatment for hospitalized patients.

The International Steering Committee formulated the recommendation in light of the evidence for hydroxychloroquine vs standard-of-care and for lopinavir/ritonavir vs standard-of-care from the Solidarity trial interim results, and from a review of the evidence from all trials presented at the 1-2 July WHO Summit on COVID-19 research and innovation.

These interim trial results show that hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care. Solidarity trial investigators will interrupt the trials with immediate effect.

For each of the drugs, the interim results do not provide solid evidence of increased mortality. There were, however, some associated safety signals in the clinical laboratory findings of the add-on Discovery trial, a participant in the Solidarity trial. These will also be reported in the peer-reviewed publication.

This decision applies only to the conduct of the Solidarity trial in hospitalized patients and does not affect the possible evaluation in other studies of hydroxychloroquine or lopinavir/ritonavir in non-hospitalized patients or as pre- or post-exposure prophylaxis for COVID-19. The interim Solidarity results are now being readied for peer-reviewed publication.

Source


Tags assigned to this article:
coronaviruscovid-19

You may have an interest in also reading…

IMF: Central, Eastern, and Southeastern Europe After COVID-19 – Securing the Recovery Through Wise Public Investment

The COVID-19 pandemic is taking a sizable toll on the outlook for Central, Eastern, and Southeastern Europe. The region is

Heads of WTO, WHO cite importance of open trade in ensuring flow of vital medical supplies

WTO Director-General Roberto Azevêdo and World Health Organization Director-General Tedros Adhanom Ghebreyesus issued a joint statement on 20 April underlining

New WTO working group established to deepen trade and gender discussions

A group of WTO members agreed to establish an Informal Working Group on Trade and Gender on 23 September, marking